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Aging Mouse Models Reveal
Complex Tumor-Microenvironment
Interactions in Cancer Progression
Hidetoshi Mori 1*, Robert D. Cardiff 1,2 and Alexander D. Borowsky 1,2
1Center for Comparative Medicine, University of California, Davis, Davis, CA, United States, 2Department of Pathology and
Laboratory Medicine, School of Medicine, University of California, Davis, Davis, CA, United States
Mouse models and genetically engineered mouse models (GEMM) are essential
experimental tools for the understanding molecular mechanisms within complex
biological systems. GEMM are especially useful for inferencing phenocopy information
to genetic human diseases such as breast cancer. Human breast cancer modeling in
mice most commonly employs mammary epithelial-specific promoters to investigate
gene function(s) and, in particular, putative oncogenes. Models are specifically useful in
the mammary epithelial cell in the context of the complete mammary gland environment.
Gene targeted knockout mice including conditional targeting to specific mammary cells
can reveal developmental defects in mammary organogenesis and demonstrate the
importance of putative tumor suppressor genes. Some of these models demonstrate
a non-traditional type of tumor suppression which involves interplay between the tumor
susceptible cell and its host/environment. These GEMM help to reveal the processes
of cancer progression beyond those intrinsic to cancer cells. Furthermore, the, analysis
of mouse models requires appropriate consideration of mouse strain, background, and
environmental factors. In this review, we compare aging-related factors in mouse models
for breast cancer. We introduce databases of GEMM attributes and colony functional
variations.
Keywords: genetically engineeredmousemodels (GEMMs), gene knockout mice, aging, mammary tumorigenesis,
mouse strain
PREAMBLE
Since the introduction of gland cleared mammary fat pad by DeOme and associates (Deome et al.,
1959), mammary gland and mammary cell transplantation has been used to study aging in the
mammary gland. One of the initial observations was that normal mammary epithelium had a
limited capacity to fill the mammary fat pad and the original mammary epithelium would not
grow after five or so serial transplants (Daniel et al., 1968). Serial transplant senescence defines
a property of normal mammary epithelium, with “immortalization” or non-senescence proof of a
neoplastic transformation (Daniel et al., 1968, 1975). Subsequently, this “test-by-transplantation”
became the basis for the early descriptions of mammary gland stem cells their “committed”
intermediates (Smith and Medina, 1988, 2008). This experiment laid the foundation for modern
stem cell research. Although endocrine influence on the mammary gland was well-understood at
the time, additional environmental factors were somewhat ignored (Young et al., 1971; Daniel et al.,
1983) and not widely applied to problems in neoplasia.
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Genetic engineering technology brought a new scientific
generation into the study of experimental mammary
tumorigenesis. The literature produced deals only indirectly
with the problems of aging and mouse mammary tumorigenesis.
Our objective is to organize and discuss this abundant data set
specifically in the context of aging-related cancer.
BACKGROUND
Breast cancer is an aging-related disease. According to American
Cancer Society (www.cancer.org), multiple factors have been
identified as risk factors. These factors include aging, gene
mutations, ethnicity, breast tissue density, early menarche,
menopause after age 55, exposure to certain chemicals and life
style related factors (e.g., parity, breast feeding, birth control,
hormone therapy, drinking alcohol, and obese). Each of the
factors indicated above are also linking to aging. For example,
first birth at an older age results in a higher risk (MacMahon
et al., 1970) and the risk after parity is sustained in a woman
who has her first pregnancy at an older age (Albrektsen et al.,
2005; Meier-Abt and Bentires-Alj, 2014). Like the famous
“nun study” suggesting that parity was protective, more recent
studies comparing nulliparous and parous Norwegian women
demonstrated that parity has a slight protective effect that
increases with age (Albrektsen et al., 2005). The mechanism of
increased cancer risk related to these proven epidemiological
factors has been extensively investigated and debated. Clearly,
endocrine changes with time affects incidence, but also raises a
central conundrum of breast cancer risk—why does cancer risk
increase with advancing age even as endogenous estrogen levels
drop after menopause? And, for our purposes in this review, do
mice model this change? Mice do not go through a “menopause”
per se, but their reproductive capacity and hormonal levels,
including estrogen, decline around 1 year of age (Nelson et al.,
1982; Finch et al., 1984). Perhaps the better question is—do
mice live long enough to get mammary cancer? This is where
genetic engineering can help. Originally construed as a simple,
cell intrinsic, proof of oncogene function, like a modern Koch’s
postulate for oncogenes, these genetic alterations, in many cases,
instead result in a mild acceleration of the risk for developing
mammary tumors. These genotypes are the important GEMM for
studying breast cancer risk, risk modifiers, and aging.
A wide variety of GEMM have been generated to study
beast and other cancers. Strong mammary epithelial specific-
promoters driving potent oncogenes are most commonly used,
with the obvious practical benefit of rapid and highly penetrant
cancer development—a clear practical benefit to experimental
design and execution (Borowsky, 2011). Mouse mammary tumor
virus long terminal repeat (MMTV-LTR) (note: this construct
does not include other viral elements, such as T antigens,
and is not transforming by itself) and milk protein promoters
such as whey acidic protein (Wap) and beta lactoglobulin
(Blg) promoters are the most extensively used for transducing
breast cancer-related genes in mouse mammary epithelial cells.
However, the target molecule under MMTV-LTR promotion is
transduced even in early developmental stages (Wagner et al.,
2001), and most tumors with the MMTV-LTR as a promoter
induce strong growth signals at a relatively early age in the
mouse life span. On the other hand, Wap RNA expression is
up-regulated by lactogenic hormones and is induced during the
late stages of parturition and lactation (Pittius et al., 1988). This
trait makes the Wap promoter a useful tool for analyzing the
pregnancy-dependent effects. However, the transgene underWap
promoter activity is also activated in nulliparous mice and in
early pre-lactation (Pittius et al., 1988) as well as during the early
stages of involution (Wagner et al., 1997). The promoter activity
is, however, the highest during pre-lactation/lactation.
Tumors arising in GEMM with transgenes constructed from
strong epithelial promoters can be difficult to interpret. The
promoters themselves are hormonally regulated, so that studying
hormone blockers or depletion in these models can yield the
trivial mechanistic result of down-regulation of the transgene.
There is also the problem of simultaneous development and
progression of multiple primary tumors, sometimes making the
progression of a specific, single tumor impossible to study.
Gene knockout (GKO) mice also have been generated for
breast cancer research and exhibit differences in mammary gland
development and/or tumorigenesis. The GKOmice are generally
designed to test for tumor suppressor type of genes. Therefore,
the GKO does not usually result in the neoplastic alteration by
itself. However, tumor suppressor GKOs often result in dramatic
changes in tumor kinetics when crossed with an oncogenic
transgene GEMM. Conditional gene knockouts using Cre-LOX
technology and using mammary luminal specific (MMTV-LTR-
Cre; Wap-Cre; Blg-Cre) or basal specific (K14- or K5-Cre)
targeting are useful to focus on the molecular involvement in
epithelial cells but may not reflect the importance of changes in
the microenvironment during breast cancer progression.
The analysis of aging effects in breast cancer progression
requires an understanding of senescence of any cell in the
microenvironment as well as the cancer cell. Therefore, such
phenomena as the immune cell activities on clearing damaged
senescent cells must be considered. However, very little is
known about how these microenvironment and immune cell
activities are involved in GEMM. Variations in phenotypes
depending on the mouse strain’s background which also limits
comparisons with other models. Further, the “environmental”
factors, such as mouse housing, cycles of circadian rhythm, diet,
viral—and bacterial-infections, can also affect the phenotype.
However, environmental variables are almost completely ignored
when models are compared. These environmental factors are
also known as modifiers for immune cell activities and are
important for immune cell-related aging. In this report, we
introduce GEMM for breast cancer research which might
be useful tools for analyzing the effects of aging and
microenvironment.
AGING PARAMETERS IN GEMM
Aging in the mouse has been extensively described and
discussed in literature and in monographic compendiums about
pathobiology (Carlton et al., 2001) and physiology (Flurkey et al.,
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2007). The pathobiology has been updated for application to
GEMM (Brayton et al., 2012). Numerous biomarkers for mouse
aging and senescence have been described and applied. For
example, the use of T-cell populations and IGF-1 levels have been
widely used but other markers are also quite useful (Flurkey et al.,
2007).
Endocrine factors have also been analyzed for aging related
study in mouse (Flurkey et al., 2007). The status of ovarian
hormone production is key to understanding aging-related
hormone receptor positive neoplasms in mouse and human
mammary neoplasms. Although estrogen receptor (ER) positive
mammary tumors in GEMM have been analyzed in prior studies
(reviewed in Dabydeen and Furth, 2014), not all models have
been tested for hormone dependent- and independent-tumors
actions using ovariectomy or hormone disrupting chemicals.
Ovarian ablation experiments are important in GEMM because
aged mice are not anovulatory as in humans (see the section
below: “Aging in the human breast and mouse mammary gland
and microenvironment”).
In the absence of biomarker data, life span is used for
comparing potential aging effects on tumorigenesis in GEMM.
Since the standard measurement of biomarkers have not been
applied to GEMM of breast cancer and few, if any, laboratories
keep colonies with sufficient populations to have accurate length
of life data. We have arbitrarily adapted Harrison’s life stages
graph to estimate Mature (3–6 months), Middle Age (10–14
months), and Old (18–24 months) (Flurkey et al., 2007). Further,
we have converted the numbers from months to weeks or days.
The only data available, in most tumor related papers, is the T50
of tumorigenesis. These data can be misleading because of the
chimeric populations used in some studies. However, the T50 is a
useful metric for comparison.
MAMMARY TUMORS IN MMTV-LTR AND
WAP PROMOTER DRIVEN MOUSE
MODELS
MMTV-LTR was first used to generate Tg(MMTV-Myc) in 1984
(Stewart et al., 1984). The activity of this promoter is sensitive
to progesterone and dihydrotestosterone but not to estrogen
(Otten et al., 1988). It can also be affected by the combinations
of other factors, such as cell density, nutrition, growth factor, and
hormones (Young et al., 1975; Cardiff et al., 1976). Currently,
114 GEMM lines targeting 45 genes (except for tTA, rtTA, and
luc) have been registered in Mouse Genome Informatics (MGI)
(Figure 1) (Bult et al., 2015; Blake et al., 2017; Finger et al., 2017).
Of these 45 genes, human or mouse derived, 27 genes promoted
by the MMTV-LTR developed mammary tumors. Whereas the
median tumor latency time (a.k.a. median tumor-free latency;
T50) is not always indicated or reported and the estimated
T50 is variable ranging from 4 weeks to more than a year (52
weeks). Since MMTV-LTR is also active in embryonic tissues,
the gene induction can be higher in developmental stages of
mammary gland growth (Wagner et al., 2001). Transgenes with
strong signaling inducing activity (i.e., PyMT, Erbb2, Catnb,
Nras, Haras) form palpable tumors at relatively young ages.
However, interestingly, the T50 in several MMTV-LTR driven
GEMM are longer than a year. Remember that according to
Flurkey et al. mice aged 10–14 months are equivalent to 38–47
years middle-aged human, and 18–24months are equivalent to
56–69 years older human (Flurkey et al., 2007).
In MMTV-LTR driven tumor-forming GEMM (Figure 1),
mice with T50 longer than 10months (43 weeks) or older number
13 including: Myc (Cardiff et al., 1991), Espl1 (Mukherjee et al.,
2014), constitutively active SRC (Y527F) (Webster et al., 1995),
auto-phosphorylation mutant Erbb2 (NYPD) (Dankort et al.,
2001), Catnb (Imbert et al., 2001), DMP1β (Maglic et al., 2015),
CCND1 (Wang et al., 1994), activated rat neu oncogene tagged
with CD4 and CD8 epitopes (OT-I/OT-II) (Wall et al., 2007),
Cdc37 (Stepanova et al., 2000), Myc mutant insensitive to KRas
signal (T58A) (Andrechek et al., 2009), AURKA (Wang et al.,
2006) and dominant negative type II TGFb receptor (TGFBR2)
(Gorska et al., 1998).
Some models, when analyzed, demonstrate that parity
facilitates tumorigenesis. MMTV-Catnb (Imbert et al., 2001),
MMTV-Myc (Stewart et al., 1984; Cardiff et al., 1991), and
MMTV-DMTF1 (Maglic et al., 2015) in parous mice have shorter
T50 than nulliparous females. The MMTV-Espl GEMM forms
tumor only with pregnancy (Mukherjee et al., 2014). Similarly,
MMTV-PTGS2 nulliparous female mice do not develop tumors
in, but 85% ofmultiparous femalemice develop tumors (Liu et al.,
2001).
Even GEMMs without tumor, crossbred to a GEMM with
mammary tumors often results in different tumor kinetics.
For example, the following crosses all resulted in accelerated
tumor development: MMTV-MAT × MMTV-neu (Rudolph-
Owen et al., 1998), MMTV-Vegfa × MMTV-neuYD (Oshima
et al., 2004), MMTV-Akt1∗T308D∗S473D × MMTV-PyMT
(Hutchinson et al., 2001). In contrast, MMTV-DTX1 × MMTV-
HRas (or MMTV-cMyc) bigenic mice had better survival
(Kiaris et al., 2004). Some GEMM publications which do not
have sufficient information to estimate T50, are indicated in
Supplementary Data Sheet 1.
Wap-promoter driven mouse model was first used to make
Wap-HRAS (Andres et al., 1987; Nielsen et al., 1991). In 2017,
25 GEMM lines targeting 16 genes are registered in MGI. Wap
promoter activity has been used to transactivate target cDNA
in mammary epithelial cells during pre-lactation and lactation.
These models might be useful for the study of parity-dependent
tumorigenesis. In these GEMM, 13 genes transduced with Wap-
promoter formed mammary tumor (Figure 2). Although the
pregnancy usually occurs in younger, reproductive age mice, the
T50s inWap promoter driven GEMM vary widely from younger
(21 weeks) to older (81 weeks) females. Examples include Wap
promoter driving the expression of the intracellular domain of
Notch4 with a longer T50 (43 weeks<) (nulliparous) (Gallahan
et al., 1996), a truncated form of the SV40 T-antigen (T121)
(Simin et al., 2004), SV40 large T (Tag) (Tzeng et al., 1993; Goetz
et al., 2001), TDGF1 (Sun et al., 2005), SV40 small T (tAg) (Tzeng
et al., 1993; Goetz et al., 2001) and constitutively active ratMmp3
(Sympson et al., 1994).
Parity enhances tumorigenesis in the Wap-Notch4 (Gallahan
et al., 1996). Wap-Shh is a Wap promoter driven GEMM which
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FIGURE 1 | Tumor latency in MMTV-LTR driven GEMM. A graph indicates a tumor latency (T50, weeks) in each MMTV-LTR driven GEMM. GEMM in Mouse Gemone
Informatics (http://www.informatics.jax.org/) are shown. Blue and red bars indicate nulliparous and multiparous, respectively. Green line indicates 43 weeks (10
months) when the mouse is in age equivalent in mid-age human (Flurkey et al., 2007). If each publication described T50 or a graph for percentage of tumor free, T50
is indicated as weeks. If the publication does not indicate these parameters but has enough information to predict T50, indicated T50 were calculated. MMTV-LTR
driven GEMM, which does not have sufficient information to calculate T50 or have other information (e.g., non-palpable tumor but microscopic observation for
hyperplastic region), are summarized in additional Supplementary Data Sheet 1.
does not develop parity-dependent tumors other than in Cre
expressing GEMM (García-Zaragoza et al., 2012). Interestingly,
Wap-Myc showed the shortest T50 (21 weeks) (Schoenenberger
et al., 1988) amongst the Wap-promoter driven GEMM. In
contrast, MMTV-Myc showed longer latency (T50 = 43 weeks)
(Stewart et al., 1984; Cardiff et al., 1991). This difference
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FIGURE 2 | Tumor latency in Wap-promoter driven GEMM. A graph indicates
a tumor latency (T50, weeks) in each Wap-promoter driven GEMM. Blue and
red bars indicate nulliparous and multiparous, respectively. Green line indicates
43 weeks (10 months). As same as MMTV-LTR driven GEMM, if each
publication does not indicate T50, the T50 is estimated from the information.
Additional information for GEMM not listed on this graph is available in
Supplementary Data Sheet 1.
could reflect the transient Myc expression in Wap-Myc versus
the sustained expression of Myc in MMTV-Myc. These Wap-
promoted GEMM with longer T50s may provide useful clues for
comparison of parity-related human breast cancer (Albrektsen
et al., 2005; Meier-Abt and Bentires-Alj, 2014) and the effects
of lactation in reducing human breast cancer risk (Ursin et al.,
2004). For example, Wap-Myc (or other Wap-promoter driven)
mice can have induced pregnancy at different ages and analyzed
for tumorigenesis to identify the mechanism of higher risk in the
first pregnancy in older age. The experiment can also be expanded
to identify the mechanisms of multiparity dependent-or breast
feeding dependent-risk reduction for breast cancer.
GKO MOUSE MODELS AND MAMMARY
TUMORS
GKO mice have also been used to analyze the molecular
mechanisms in breast cancer. The Trp53 (p53) deletion is
best known GKO mouse that develops mammary tumors. It
is based on the study of heterozygous deletions found in Li-
Fraumeni syndrome (Donehower, 1996). p53 heterozygous and
homozygous knockout mice on mixed genetic backgrounds have
tumor-free survivals (T50) of 78 and 18 weeks, respectively
(Donehower, 1996). In contrast, on a pure Balb/c background p53
heterozygote and homozygous knockout mice have tumor-free
survivals (T50) at 54 and 15.4 weeks respectively (Kuperwasser
et al., 2000). Although these p53 GKO mice develop various
types of tumor, palpable mammary tumors are rare on the
mixed backgrounds. The Balb/c model had “mammary tumors”
at the rate of 78%. However, microscopic examination of the
masses revealed that 68% of “tumors” consisted of palpable
masses were stromal abnormalities and sarcomas rather than
epithelial tumors (Kuperwasser et al., 2000). Other studies with
p53 deletions targeted to the mammary gland resulted in forming
heterogeneous types of mammary tumors, suggesting a second
event with different oncogenic drivers (Cardiff et al., 2006).
We reported that a signal transducer and activator of
transcription 1 (Stat1) GKO in 129S6/SvEvTac background has
a reduced branching morphogenesis during mammary gland
development (Chen J. Q. et al., 2015). Most important, this GKO
developed ER positive luminal-subtype mammary carcinomas
with T50 at 91 weeks in nulliparous mice and 78 weeks in
parous mice (Mori et al., 2017). This is a rare GKO which forms
a morphologically uniform type of mammary tumor without
crossing with the other GEMM or p53 GKO. This unique GKO
will be discussed in more detail below.
Some studies using GKO crossed with tumorigenic GEMM
targeting mammary epithelium have been instructive. Cell-cell
association is also a microenvironmental signal to epithelial cells
and provides important signals to polarize epithelial cells. Cdh1
f/f; Trp53 f/f is a Cre-dependent conditional deletion of E-
cadherin (Cdh1) and p53 resulting in double GKO only in cells
(and their progeny) that express the bacterial (exogenous) Cre
recombinase. When crossed with K14-Cre (Derksen et al., 2006)
orWap-Cre (Derksen et al., 2011) to conditionally knockoutCdh1
and p53 in mammary basal epithelial cells or epithelial cells,
respectively, the resultingK14-Cre; Cdh1 f/f; Trp53 f/+ developed
mammary and skin tumors with T50 of 71 weeks. However, the
homozygous deletions developed tumors with shorter T50s: K14-
Cre; Cdh1 f/f; Trp53 f/f (T50 = 31 weeks) and K14-Cre; Cdh1
f/+ (or +/+); Trp53 f/f (T50 = 48 weeks) (Derksen et al., 2006).
In contrast, the Wap promoter versions of similar crosses, Wap-
Cre; Cdh1 f/f; Trp53 f/+, formed mammary tumor with T50 of
83 weeks (calculated from Kaplan-Meier tumor free survival)
which was much longer latency than Wap-Cre; Cdh1 f/f; Trp53
f/f (T50 = 28 weeks), Wap-Cre; Cdh1 f/+; Trp53 f/f (T50 = 45
weeks), and Wap-Cre; Cdh1+/+; Trp53 f/f (T50 = 42 weeks)
(Derksen et al., 2011). In both K14-Cre and Wap-Cre, genotype
with Cdh1 f/f; Trp53 f/+ exhibited prolonged latency, suggesting
that these GEMM might be useful for the study of aging-related
mammary tumorigenesis. Cdh1 GKO model as another example
of a homozygous GKO that is not sufficient for tumorigenesis but
requires a cross with other GEMM to induce tumors.
Defects in BRCA1 and BRCA2 genes have been recognized as
risk factors for human breast cancer and ovarian cancer (Narod
and Foulkes, 2004). Brca1KO and Brca2KO have been developed
with deletions in different exons. Most of the homozygous
BrcaKO (mutants of Brca1KO and Brca2KO) were embryonic
lethal (Evers and Jonkers, 2006). Conditional KO models of
exon11 of Brca1 (Brca1Ko/Co: mouse carrying a Brca1-null allele
Brca1Ko22 and a conditional allele Brca1Co crossed with WAP-
Cre or MMTV-Cre) (Xu et al., 1999) have been analyzed for
BRCA1 related studies. Females of these Brca1 GEMM do not
form mammary tumors in the first 10 months of life. Within
10–13 months they do develop a tumor with low incidences
of 2 of 13 Brca1Ko/Co; WAP-Cre and 3 of 10 Brca1Ko/Co;
MMTV-Cre. These lower rates of tumorigenesis are increased
and accelerated in crosses with Trp53 heterozygote: Brca1Ko/Co;
MMTV-Cre; Trp53+/− mice (8 out of 11 between 6 and 8 months
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age) (Xu et al., 1999). The low incidence and prolonged latency
suggest that these GEMMs could be useful for aging studies.
However, like the majority of examples, to date these studies have
not specifically emphasized “aging processes” in these models.
MOUSE STRAINS AND THEIR BASIC
CHARACTERISTICS
Comparison of mouse models should be done in same
background strain because of the intrinsic variation of
phenotypes in each strain. Backcrossing GEMM to adjust
the strain requires time, effort, and money. Any combination
of these factors can be the reasons for avoiding breeding to
homozygosity. But why this is important? Hunter’s classical
study of the MMTV- PyMT in 20 different background strains
document the effect of genetic background a single transgene
raised in the same colony (Lifsted et al., 1998). The F1 crosses
exhibited different tumor latencies and different metastatic
potentials. Studies from other facilities show that MMTV-PyMT
had a T50 in C57BL/6: MMTV-PyMT of 92 days (14 weeks)
as compared to the shorter T50 (43 days; 7 weeks) in FVB:
MMTV-PyMT (Davie et al., 2007).
The normal life span in each colony is critical for the
evaluation of any age-related study. Each inbred mouse strain
has a different life span. Studies from the Jackson Laboratory
have reported the comparison of survival rates from 12 to
20 months. They showed that the survival rate in C57BL/6,
129S1/SvlmJ, and FVB/NJ are almost identical (Sundberg et al.,
2011). However, the survival rate at 20months is lower in FVB/NJ
(Sundberg et al., 2011). Therefore, the longevity is variable in
different mouse strains. Comparison of life span in 32 inbred
strains showed life spans that vary with gender and strain. For
example, FVB/NJ (female = 760 days and male = 591 days),
129S1/SvlmJ (female = 819 days and male = 882 days) and
C57BL/6J (female = 866 days and male 901 days) are life span
in these mouse strains (Yuan et al., 2009).
The cause of the death is also variable in inbred mice. Age-
related diseases and causes of death typical of some common
strains have been documented (Brayton et al., 2012). Not
surprisingly, their comparison of end of life neoplasms in three
strains (B6, 129 and B6,129) in three institutions (UW, NTCR,
NIH) also reveal differences incidence of neoplastic and non-
neoplastic disease. These differences could be attributed to
difference in mouse housing and maintenance.
Genetic drift in isolation is another factor. For example, some
but not all FVB colonies have pituitary abnormalities. Shorter life
spans in FVB might be partially related to the pituitary gland
abnormalities (pituitary tumor 32%, pituitary hyperplasia 14%)
in aging FVB/N mice. The study showed that about 30% of aged
(>80 weeks) females also developed mammary gland tumors
(Radaelli et al., 2009). Since FVB have been the most commonly
used strain for transgenic targeting of the mammary epithelium,
investigators using this strain need to collect pituitary at the end
of the experiment.
The Brayton’s study lists the factors which can affect
mouse phenotype and experimental outcomes. Difference in
diet (calories, its contents), enrichment, housing (cage type,
density/cage, and pathogen status), ear tag, infectious agents,
light cycle, and temperature can influence all phenotypes and
experimental outcomes (Brayton et al., 2012). For example,
studies with MMTV-neu show that diet alters the percent tumor
free animals (Yang et al., 2003; Liu et al., 2005) and efficacy of
tamoxifen (Liu et al., 2005).
THE MICROENVIRONMENT
The normal mammary microenvironment of the mouse has
been extensively studied. However, most reviews emphasize the
immune system or hypoxia (Rothschild and Banerjee, 2015).
With the success of immunotherapy syngeneic tumor transplant
models have become extremely useful. Without a doubt, all
the other cell populations deserve mention. Whereas many
factors play major roles in the epithelial-environmental, there
is almost no information with the lack of mouse models of
microenvironmental factor and aging. As examples of some of
the molecules, we discuss herein the metalloproteinases and
adhesion molecules.
Extracellular proteins, cell surface molecules and signaling
molecules are the targets for the analysis of stromal-epithelial
interactions. Some molecules involved in association between
extracellular matrices (ECMs) and cell surface receptors have
been analyzed in GKOs. These GKOs are often crossed with
tumorigenic MMTV-LTR or Wap-promoter driven GEMM,
because GKO of these molecules might not be sufficient to
form palpable mammary tumors by themselves. As summarized
in Supplementary Data Sheet 1, ECM molecule-related GKOs
have been crossed mostly withMMTV-PyMT andMMTV-neu.
For example, metalloproteinases (matrix metalloproteinase:
MMP; a disintegrin and metalloprotease: ADAM) are a family of
zinc binding type extracellular proteinases which process ECM
molecules and surface molecules (Wolfsberg et al., 1995; Nagase
and Woessner, 1999). These molecules are known to be involved
in various physiopathological activities including development,
tissue remodeling and cancer cell invasion (Rudolph-Owen et al.,
1998; Seiki et al., 2003; Fata et al., 2007; Reiss and Saftig, 2009;
Mori et al., 2013). Some of these MMP genes (Mmp-8, and -
14) and ADAMs (Adam-12 and -ts1) have been used in studies
of mammary tumor progression by crossing GKO with MMTV-
PyMT. Deletion of Adam genes delay PyMT tumor growth and
metastasis (Fröhlich et al., 2011; Ricciardelli et al., 2011). Deletion
of the Mmp genes had a different effect in PyMT tumorigenesis.
Interestingly, both Mmp8KO and Mmp14KO in bigenic crosses
with PyMT developed tumors earlier than WT-PyMT control
(Szabova et al., 2008; Decock et al., 2015). Lung metastasis of
PyMT tumor was reduced in bigenic mice with Mmp14KO
(Szabova et al., 2008). In contrast, Mmp8 deletion enhanced
PyMT pulmonary metastasis (Decock et al., 2015).
Tissue inhibitor for metalloproteinase 3 (Timp3) GKO when
crossed with MMTV-PyMT and MMTV-neu inhibited tumor
growth and lung metastasis (Jackson et al., 2015). The T50 in
MMTV-neu in the absence of Timp3 was ∼76 weeks compared
with ∼31 weeks in Timp3+/+; MMTV-neu (calculated from
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Kaplan-Meier curve of the age at first detection of tumor)
(Jackson et al., 2015), suggesting that Timp3−/− MMTV-neu
might be another suitable model for studying aging-related breast
cancer progression. Whereas Timp3−/−; MMTV-PyMT tumor
delayed T50 (∼13 weeks compared with control: 10 weeks),
tumor growth was accelerated once tumor was formed (Jackson
et al., 2015). Since TIMP3 has broad-spectral inhibition activity
on both MMPs and ADAMs (Brew and Nagase, 2010; Murphy,
2011), TIMP3 target protease activities might be differentially
involved in tumor growth and metastatic conversion. Once
spatiotemporal distributions of MMPs, ADAMs, and TIMP3
were identified duringmammary tumor progression are revealed,
the TIMP3 effects on each target protease can be understood.
Nonetheless, the delay in tumorigenesis in Timp3−/−; MMTV-
neu could be another useful model for studying age-related
mammary tumorigenesis.
Other GKO mice crossed with MMTV-PyMT and -neu have
also been used to study the functions of cell adhesion molecules’
involvement during the neoplastic process. In particular, many
of these molecules mediate the association between cells and
microenvironment. Since PyMT tumors forms earlier than
neu tumors, the PyMT tumor model may not be as good a
model for the study of aging. However, accelerating or delaying
tumorigenesis in neu- or PyMT-tumor might reveal the function
of target molecules that may affect aging.
The models described here are GKO crossed with other
mammary tumor models. To analyze the association between
collagen and the receptor (integrin a2b1), Itga2KOwas developed
(Chen et al., 2002). This Itga2KO was then crossed withMMTV-
neu (Ramirez et al., 2011). The bigenic cross showed the earlier
T50 (31 weeks) with higher metastatic levels then the comparable
Itga2+/+; MMTV-neu control (33 weeks). CD151, a tetraspanin
molecule associating with laminin binding integrins (Hemler,
2005), was knocked out and the mice crossed with MMTV-
neu to study the molecular interactions with anErbB2 driven
cancer (Deng et al., 2012). The T50 of the bigenic CD151−/−;
MMTV-neu was 48 weeks which indicates slower tumor growth
compared with the control 38 weeks in the control CD151+/+;
MMTV-neumice.
The GKO of Hic5, a focal adhesion scaffold/adaptor protein,
was crossed with MMTV-PyMT and the T50 was 9 weeks
longer than the heterozygous knockouts with Hic5+/−; MMTV-
PyMT (Goreczny et al., 2017). Protein-tyrosine phosphatase
1B (PTP1B), which is involved in regulating signals between
cell and microenvironment, was knocked out and crossed
with MMTV-PyMT and -neu (Bentires-Alj and Neel, 2007).
Interestingly, Ptp1b−/−; MMTV-neu exhibited a greatly reduced
tumorigenesis of neu tumor (27% mice formed tumors at 69
weeks) as comparing with Ptp1b+/−; MMTV-neu and Ptp1b+/+;
MMTV-neu (T50 = 61 weeks and 57 weeks respectively).
Ptp1b−/−; MMTV-PyMT did not, however, significantly delay
PyMT tumor growth (Bentires-Alj and Neel, 2007). Some
mammary tumor forming GEMM are also used to inhibit
target molecule’s activity (MMP9, Lysyl oxidase) or crossed
with transgenic of mutant protein (e.g., collagenase resistant
type I collagen alpha1 chain, Col1a1) are indicated in
Supplementary Data Sheet 1.
These mouse models are useful for the study of various
aspects of tumor progression. The mammary promoters
(MMTV-LTR, Wap-, and K14-), however, are activated in
other cells in different organs. MMTV-Cre; Gt(ROSA)26Sor
transgenics demonstrate that the MMTV-LTR promoter
actively transduces Cre in a variety of non-mammary tissues
(e.g., salivary gland, skin, seminal vesicles, lymphocytes,
megakaryocytes, erythroid cells, etc.) (Wagner et al., 2001).
In addition, three MMTV-Cre promoted lines showed the
defects in nursing pups; line A showed impairment in
lactation, line F completely failed to nurse, and line D was
normal.
Wap-cre; Tg(CMV-nlacZ)1Pgr showed Cre expression in
brain, muscle and testes, and one line had Cre expression in
mammary gland and the brain (Wagner et al., 1997). K14-
Cre (Vasioukhin et al., 1999), K5-Cre (Tarutani et al., 1997),
and Lgr-CreERT2 (Kinzel et al., 2014) have also been used
to conditionally knockout gene targets in mammary epithelial
cells (Taddei et al., 2008; Koren et al., 2015; Liu et al., 2016).
These promoters were originally developed to study skin tissue
(Tarutani et al., 1997; Vasioukhin et al., 1999; Kinzel et al.,
2014) and other organs (gut and kidney) (Kinzel et al., 2014).
Thus, these promoter activities are not specific to mammary
epithelial cells. This suggests that the effect onmammary gland in
GKOs crossed with these Cre expressing GEMM might be more
complex than mammary epithelial-specific promoters. Once
aging dependent or independent inflammatory activity occurs
in one organ, the activity of immune cells will be modified and
can affect other organs in the same animal. In addition, crossing
these models with different mouse background strains can cause
the variations in phenotypes (e.g., immune cell activity, drug
efficacy, tumorigenesis). In next section, we summarize these
parameters.
AGING IN IMMUNE CELLS
The Jackson Laboratory’s analysis of immune cell populations
in peripheral blood in 6 months old inbred mice demonstrates
that lymphocytes in female (F) and male (M) differ between
strains and genders (Petkova et al., 2008). Examples include
C57BL/6J which are F: 71.5% and M:78.2%, FVB/NJ are F:79.9%
andM:52.5% and 129S1/SvlmJ are F:49.4% andM:60.5%(Petkova
et al., 2008) Monocytes in C57BL/6J are F:4.47% and M:7.62%,
FVB/NJ are F:5.79% and M:6.6% and 129S1/SvlmJ are F:8.3%
and M:8.61% (Petkova et al., 2008). More importantly, these
percentages of immune cells and the immune cell activities might
also be different with age of the mouse strain. Studies of aging
in immune cells, named “inflammaging” (Baylis et al., 2013;
Salvioli et al., 2013; Franceschi and Campisi, 2014; Franceschi
et al., 2017), indicate that each immune cell lineage and their
activities change with age. These age-related changes can directly
affect tumor initiation and progression. Since immune cells are
a factor in “tumor microenvironment” and important in clearing
damaged cells (such as senescence cells), immune cell activities in
aged mice might also provide hints to decipher the link between
aging and breast cancer.
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LYMPHOCYTES
Decreased lymphoid progenitors and involution of the thymus
occur during aging (Linton and Dorshkind, 2004; Palmer, 2013).
This results in a decrease in T-cell output and shifts in cell
types from naïve (CD62Lhigh CD44low) to memory T-cells
(CD62Llow CD44high) (Shimatani et al., 2009; Sprent and Surh,
2011; Goreczny et al., 2017). These aging memory T-cells are
PD1+ and CD153+CD44high CD4+ (Sato et al., 2017). They
have the same phenotype as senescence associated T-cells found
in lupus pathogenesis (Tahir et al., 2015), suggesting that the
aging dependent increase in CD4+ T-cells might also be involved
in increased risk of autoimmunity. Memory CD8+T cells are also
increased in aged mice (Chiu et al., 2013). The memory CD8+
T cells in older mouse expand the numbers of effector CD8+ T
cells in LCMV infection compared with younger mouse derived
memory CD8+ T cells (Eberlein et al., 2016). This critical change
in T cells could be an anti-pathogen defense system in aged mice
with less naïve T-cells.
In aged humans, decreased memory B-cells and increased
naïve B-cells are observed (Chong et al., 2005). In mice, B-
cells numbers are decreased with aging because of decreased
precursors in bone marrow (Riley et al., 1991). This is further
defined as the defect in the process between pro-B and pre-B
maturation in aged mice (Stephan et al., 1996). The defect in pro-
B to pre-B maturation in aged mice is attributed to insufficient
levels of IL-7 (Fleming and Paige, 2001). In MMTV-PyMT
mice, splenic B-cells are increased, This might be considered as
evidence of inhibitory factors secreted from the PyMT tumor
cells that inhibit B-cell progenitor proliferation and maturation
(Moreau et al., 2016).
Regulatory T cells (Treg: a.k.a. suppressor T cells) are
also altered in aged mice. CD4+/CD25+/Foxp3+ and
CD8+/CD25+/Foxp3+ Treg cells are almost two times
higher in spleens and lymph nodes from aged mice, and prevents
the activation of immune response (Sharma et al., 2006).
Increased Treg are also observed in both peripheral blood and
tumor microenvironment of invasive breast cancers (Liyanage
et al., 2002). C57BL/6 with Foxp3 knocked-out/knock-in human
diphtheria toxin receptor (DTR; Foxp3DTR) (Kim et al., 2007)
is a GEMM for analyzing Treg activities in the presence or
the absence of diphtheria toxin (DT). Orthotopic injection
of a C57BL/6; MMTV-PyMT derived mammary tumor into
Foxp3DTR treated with DT results in reduction of PyMT tumor
growth. Enhanced apoptosis was noted with proliferation of
naïve CD4+ cells and CD8+ cells (Bos et al., 2013).
MACROPHAGES
Macrophage phagocytosis is involved in clearing apoptotic
cells and is important for maintaining tissue homeostasis.
However, aging reduces the macrophage capacity for clearing
apoptotic cells (Aprahamian et al., 2008). Moreover, macrophage
treated with tunicamycin, an inducer for endoplasmic reticulum
stress, showed that macrophages isolated aged mice have more
apoptosis compared with macrophages from younger mice (Song
et al., 2013). Macrophage activation is also altered in aging.
Cytokine induction to direct macrophage to M1 is increased
in aged mice, but the M2 induction is decreased. Conversely,
induction to M1 is weaker in younger mice, but induction to M2
is stronger (Lee et al., 2013).
Deletion of p53 in hepatic stellate cells (HSCs) induces fibrotic
liver tumors which have proliferating HSCs and senescence
of HSCs (Lujambio et al., 2013). Interestingly, conditioned
media from proliferating HSCs induces M2 polarization, and
contrary, conditioned media from senescent HSCs induces
M1 polarization of macrophage (Lujambio et al., 2013). The
macrophage polarization in two studies suggest that aging
reduces macrophage induction to M2 status. This might
decrease the anti-tumor activity of macrophages and facilitate
tumorigenesis. This secretion from senescence cells is called
senescence associated secretory phenotype (SASP). SASP causes
pro- and anti-tumor activities through affecting to different
types of immune cells (Rao and Jackson, 2016). Since secretion
from cells have soluble factors (e.g., cytokines, processed
proteins from cell surface) and extracellular vesicles (exosomes,
microvesicles, and apoptotic bodies) (El Andaloussi et al., 2013),
the identification of the contents within each fraction, function,
levels, and distribution is now required to understand SASP as a
part of aged microenvironment.
MYELOID DERIVED SUPPRESSOR CELLS
(MDSCS)
MDSC is a key immune cell in the control of immune cell
activities and reciprocally associates with Treg to regulate tumor
progression (Hurez et al., 2012, 2017; Marvel and Gabrilovich,
2015). MDSCs are increased in aged mice (Grizzle et al., 2007;
Enioutina et al., 2011) and human (Verschoor et al., 2013).
This age dependent MDSC expansion is regulated by Nf-kB
activity in aged mice (Flores et al., 2017). Aged mice have
increased MDSCs and less T-cell cytotoxicity compared with
young mice. The suppression of T-cell cytotoxicity is due to the
high levels of arginase activity in aged MDSCs (Grizzle et al.,
2007). Interestingly, the increase of MDSCs is also observed in
bone marrow and spleen of tumor-bearing mice compared with
naïve mice (Huang et al., 2006). These MDSCs from tumor-
bearing mice induce the development of Treg (Huang et al.,
2006) and T-cell tolerance (Kusmartsev et al., 2005; Huang et al.,
2006). These age-related tumor permissive activities of MDSCs
have been targeted for immunotherapy. Higher levels of tumor
permissive activity in aged mice can be reduced with anti-
GR1 targeting MDSCs, which reduces melanoma tumorigenesis
(Hurez et al., 2012). Aged MDSCs have higher levels of B7-H1
(a.k.a. Programmed death ligand 1, PD-L1) induced by IL-10
activity, and the inhibition of B7-H1 reduced the tumorigenesis
of Lewis lung cancer cells in aged mice (Chen S. et al., 2015).
DENDRITIC CELLS
Dendritic cells (DCs) are antigen-presenting cells and
categorized by differentiation status into conventional DCs
(cDCs), plasmacytoid DCs (pDCs), and monocyte DCs
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(moDCs). The DCs are involved in a key function on T-cell
activation (Gardner and Ruffell, 2016). Twenty six-month-old
male C57BL/6 mice (from Jackson Laboratory and maintained
at Oregon State Univ) had decreased splenic pDCs and CD8+
cDC (Wong et al., 2010). Another study with 18-month-old
female C57BL/6 mice (from State Foundation for Production
and Health Research and maintained at Instituto de Pesquisas
Biomédicas, Brazil) found reduced numbers of CD11c+ cells
but only cDCs were significantly reduced as compared with
young mice (Pereira et al., 2011). However, C57BL/6 mice (from
Animal Resources Center and maintained at The Centenary
Institute for Cancer Medicine and Cell Biology, Australia) older
than 18 months had increased cDCs in spleen and lung as
compared to young mice. In contrast, Balb/c mice did not show
the same difference between aged and young mice (Tan et al.,
2012). This study also showed by comparison of T-cell activation
of DCs from aged- and young- C57BL/6 mice no differences
in co-stimulatory molecules (CD80, CD40, and CD70) except
for CD86 (B7-2) which is reduced in aged cDCs with influenza
infection (Tan et al., 2012). However, aging effect on CD86 levels
are not differ in cDCs in above mentioned two other studies
(Wong et al., 2010; Pereira et al., 2011) and without influenza
infection (Tan et al., 2012). Thus, the difference in cDCs
might be affected by variations in mouse strain background,
gender, age, housing environment and pathogen activities. In a
ovarian tumor model (C57BL6: LSL-K-rasG12D/+p53loxP/loxP
generated from Krastm4Tyj and Trp53tm1Brn mice), DCs changed
the phenotype from immunosuppressive in the earlier stage
of tumor expansion to immunogenic in the advanced stage of
cancer (Scarlett et al., 2012), This switch suggests that the status
of DCs might indicate the checkpoint for neoplasia as it become
malignant.
NATURAL KILLER CELLS
Natural killer (NK) cell is a type of lymphocyte and an important
cell for innate immunity.
A comparison of NK cells in healthy people from 4 to 106
years of age showed that NK cells were increased in older age,
but NK activity in middle-aged subjects was weaker compared
to young subjects and to centenarians (Sansoni et al., 1993). In
mice, there were strain dependent and gender variations in a
percentage of peripheral NK cells (Petkova et al., 2008). Whereas
C57BL/6 and 129S1/SvlmJ mice have similar percentages of NK
cells between the genders (C57 female: 3.74%, male: 4.02%;
129 female: 5.5%, male: 4.66%), FBV/NJ male mice have a
significantly fewer NK cells (3.49%) than females (7.15%)
(Petkova et al., 2008). NK cells are increased in bone marrow
in aged Balb/c mice, resulting in decreased pro-B cells in aged
animals (King et al., 2009). NK cells (with different levels of CD56
and CD16) were increased in the peripheral blood from breast
cancer patients with advanced cancer but were mostly immature
and non-cytotoxic subsets (Mamessier et al., 2013). Spleen tissues
in FVB; MMTV-neu mice have almost similar number of NK
compared with wild type (WT) FVB mice while other immune
cells (T cells, DCs, MDSCs, and Tregs) are increased in FVB;
MMTV-neu (Abe et al., 2010). In C57BL/6;MMTV-PyMT, tumor
derived NK cells are immature compared with splenic NK cells.
An adaptive transplantation of splenic NK cells into tumor
resulted in decreased NK maturation, suggesting that tumor
microenvironment in MMTV-PyMT tumor determines the NK
cell maturation. The authors suggested that IL12 and TGFb are
involved in NK maturation (Krneta et al., 2016). Thus, although
NK cell numbers and activities differ in human and mouse, levels
of immaturity in NK cells is similar in human breast cancers and
mouse mammary tumors.
Immune cells’ variations and activities different between
mouse strains, genders, and age. The spatial density and
activity of each type of immune cell within the tissue is
critical to understanding associations between immune cells and
immune targeted cells (e.g., tumor cells and cells in senescence).
These associations are important for understanding age related
tumorigenesis. They are equally critical for understanding the
process of immunoediting from “elimination,” “equilibrium” to
“escape” (Schreiber et al., 2011; Mittal et al., 2014). The challenge
is now to relate the two phenomena.
AGING IN THE HUMAN BREAST AND
MOUSE MAMMARY GLAND AND
MICROENVIRONMENT
Human breasts and mouse mammary glands are functionally
similar. However, these tissues have distinct structural differences
especially during the aging process (Cardiff et al., 2018). In
puberty, human breast completes the formation of branching
collecting ducts with terminal duct lobular unit (TDLU) in
collagen fiber rich stroma. In contrast, mouse mammary glands
form a ductal branching tree without TDLU structures and
primarily embedded in adipose tissue. Mouse mammary gland
develops lobulo-alveolar structures with pregnancy. The murine
lobulo-alveolar units quickly involute within a week of weaning
(Cardiff andWellings, 1999). Human breast also expands lobulo-
alveolar units with endocrine signals during pregnancy and
parturition. In contrast to the mouse, the human involution is
slow and the TDLU structures remain (Cardiff and Wellings,
1999) with some structural variations, which correlate with time,
after the postpartum (Jindal et al., 2014). Age- related involution
in human breast occurs during perimenopause (or surgical- or
chemical induced menopause) with the atrophy of senescence,
which results in major reduction in TDLU structures (Cardiff
and Wellings, 1999; Cardiff et al., 2018). In contrast, aged mice
continue to ovulate and have estrus cycles. This limits the use
of mice to model human peri- and post-menopause conditions
(Nelson et al., 1982; Finch et al., 1984). In order to analyze
menopause dependent effects, the investigator can us surgery-
and chemical treatment-dependent induced menopause in mice.
One approach might be ovariectomy (Finch et al., 1984) which
quickly shuts down the 17β-Estradiol levels, stops the cyclicity
and quickly maximizes FSH levels (www.jax.org). Another is
4-vynylcyclohexene diepoxide (VCD) treatment, which slowly
increases FSH levels and slows down cyclicity (Brooks et al.,
2016).
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STUDYING PARITY-RELATED BREAST
CANCER AND AGING
Although multiple-pregnancies reduce the incidence rate of
human breast cancer (Albrektsen et al., 2005), the risk reduction
is sustained longer in women having a first pregnancy after 35
years old (Albrektsen et al., 2005; Meier-Abt and Bentires-Alj,
2014). Women having a first pregnancy after 30 years old also
have higher risk for breast cancer and the risk is sustained higher
until 65 years old compared with woman with nulliparous status
(Albrektsen et al., 2005; Schedin, 2006; Meier-Abt and Bentires-
Alj, 2014). The many factors (stem cells, hormone and hormone
receptor status, growth factors, cytokines, ECM, and immune
cell activities) which might be involved in these age- and parity-
dependent breast cancer are discussed elsewhere (Schedin, 2006;
Meier-Abt and Bentires-Alj, 2014).
The duration of breast-feeding is also an important factor.
Prolonged nursing (lactation) reduces the risk of breast cancer
even in aged cohort (50–64 years old)(Ursin et al., 2004).
Analyzing involvement of each factor which functions as cancer
promoting or suppressing will be a challenge for future research.
The effects of parity have been well-documented in mouse
models. Although some GEMM have prolonged tumor latency,
factors relating to aging have not been recorded in many of the
candidate models. But the current GEMM or newly generated
GEMM combined with analysis indicated in this manuscript
might give a hint for modeling the experiments. For example,
the analysis of microenvironmental factors in parity facilitated,
syngeneic orthotopic transplants in mice (Maglione et al., 2004;
Namba et al., 2004, 2005; Borowsky et al., 2005) under different
well-controlled conditions of age, parity status, parity cycles, and
milk feeding duration. Since tumors from some GEMM grow
too aggressively, tumors with slower tumor kinetics will be more
suitable for analyzing aging and parity related tumorigenesis.
STAT1 GKO AS A MODEL FOR ANALYSIS
FOR AGE RELATED MAMMARY
TUMORIGENESIS
The focus on mammary cancer in mice has been, quite
correctly, the mechanisms that make the neoplastic epithelial cell
autonomous. The transgenic mouse has provided the “Koch’s
Postulate” for modern genomic science and cancer by defining
the neoplastic potential of numerous genes and/or characterizing
genes that modify neoplastic progression. In spite of a plethora
of these mice, they have not been used to address the issue
of aging in breast cancer. Although research on the cancer
microenvironment has blossomed, the issue of aging in GEMM
has not been effectively addressed.
We have studied in detail a GEMM that includes prolonged
tumor latency, 129S6/SvEvTac: Stat1tm1Rds (129: Stat1−/−) mice
(Meraz et al., 1996), which is a unique GKO that rarely develops
mammary cancer before 1 year and has a T50 of 91 weeks (Mori
et al., 2017). The Stat1−/− females were held as long as 120
weeks (840 days) which exceeded the expected 817-day life span
of wild type 129 females. From this perspective, the T50 was
reached at 78% of the total life span. The 129: Stat1−/− provides
some insight into many of the factors considered in the review
above and the opportunity to consider the complex issues in such
models.
Other groups have demonstrated that deletion of Stat1 leads
to an increased susceptibility to mammary tumors (Klover et al.,
2010; Raven et al., 2011; Schneckenleithner et al., 2011; Chan
et al., 2012). The 129: Stat1−/− model forms mammary tumors
with a T50 at 91 weeks in nulliparous and at 78 weeks in parous
females, similar to the report from the colony in Washington
University (Chan et al., 2012). Mice younger than 32 weeks old
in our colony did not have detectable neoplastic histopathology.
Mice older than 52 weeks nulliparous without tumors had
microscopic MIN (mammary intraepithelial neoplasia; 3/32
cases), and 23/32 cases had preneoplastic MIN or tumors.
Tumor-bearing nulliparous (9/13 cases) showed lobulo-
alveolar hyperplasia even without pregnancy or exposure to
the pregnancy-associated hormones and these mice had dilated
mammary duct filled with milky white fluid. The older tumor-
bearing nulliparous, with stunted growth in mammary gland
(4/32 cases) still had underdeveloped ductal network (Chen J. Q.
et al., 2015).
The strain variation is also an important issue in Stat1
GKO. Other Stat1 GKO lines, Stat1tm1Dlv, backcrossed into
Balb/c strain also shows tumorigenesis in multiparous Stat1-
null condition with mammary tumor and disease onset at
57 weeks which is shorter latency compared with Stat1+/+
(69 weeks) (Durbin et al., 1996). Balb/c: Stat1tm1Dlv crossed
with Balb/c: MMTV-Neu shows shorter latency of Neu type
tumors as compared with Balb/c: MMTV-Neu nulliparous mice
(42 vs. 50 weeks) (Raven et al., 2011). Similarly, Stat1f/f
was crossed with FVB: Tg(MMTV-Erbb2∗,-cre)1Mul (Ursini-
Siegel et al., 2008) to conditionally knock out Stat1 gene and
simultaneously transduce neu in mammary epithelial cells, which
also results in an earlier T50 in the Stat1-null condition (50
vs. 63 weeks) (Klover et al., 2010). These two studies (Klover
et al., 2010; Raven et al., 2011) suggest STAT1 as a tumor
suppressing molecule, and the work of Klover et al. (2010)
indicates that STAT1 function in mammary epithelium is anti-
tumorigenic.
Interestingly, mammary gland development in Stat1 GKO is
only impaired in 129S6/SvEvTac (Chen J. Q. et al., 2015) but the
defect has not been observed in GKO in the Balb/c background
(Schneckenleithner et al., 2011). Mammary tumorigenesis is also
different in these two strains: 129:Stat1−/− forms homogeneous
mammary tumors with or without parity (Chan et al., 2012; Mori
et al., 2017), but Balb/c: Stat1−/− formed heterogeneous tumors
only with multiparity (Schneckenleithner et al., 2011). However,
these animals may not have been maintained long enough to
develop tumors. For example, in one study, the Balb/c: Stat1−/−
females developed mammary tumors only after being force-bred
seven times.
The interpretation of these observations is compounded by
the use of different molecular constructs for the knockout
of Stat1, which further could have influenced the outcome.
The Meraz construct deletes the N-terminus of STAT1 in
129/Sv mice, whereas residual low expression level C-terminus
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fragment remains (Meraz et al., 1996). The other construct
deleting exon 18–20 in unknown background mouse strain
does not have this fragment detected by anti-C-terminus
STAT1 (Bailey et al., 2012). However, exon 18-20 deleted
Stat1−/− mice still need to be investigated with anti-N-
terminus STAT1 and analyzed for any defect. Thus, mechanisms
leading to tumor development in 129: Stat1−/− remain
unclear.
The initial study of normal mammary development in the 129:
Stat1−/− females revealed a defect in branching morphogenesis
accompanied by abnormal terminal end buds (Chen J. Q. et al.,
2015). Given the type of molecular signaling, this could be
expected. The DeOme’s “Test-By-Transplantation” (Deome et al.,
1959) with reciprocal transplants into gland-cleared mammary
fat pads was used. The GKO epithelium developed normally in
wild type mammary fat pad. Thus, the developmental phenotype
was not intrinsic to the mammary epithelium.
Subsequent experiments proved that the GKO fat pad lacked
cytokines needed for growth. Therefore, we concluded that
the microenvironment of the fat pad was responsible for the
growth defect. Interestingly, the GKO fat pad could be stimulated
to produce adequate levels of cytokines using injections of a
progesterone and prolactin. Unfortunately, we were unable to
perform similar experiments using fat pads from older GKO
females. These experiments, however, point to the importance of
the microenvironment and the endocrine system in mammary
development and demonstrate the consequences when they are
defective.
The 129: Stat1−/− mammary tumors are morphologically
and molecularly unique, ovarian dependent tumors. The tumors
involve the neoplastic transformation of a stem cell population
that is FoxA1+, ER+, PR+ with unique atypical cells with large,
oval, moderately pleomorphic nuclei with an open chromatin
and prominent nucleoli with pale cytoplasm, named large oval
pale (LOP) cells. The characteristic of LOP cell is similar to
“committed progenitor cells” in mouse mammary gland (Smith
andMedina, 1988; Chepko and Smith, 1999) and suprabasal clear
human breast cells (Toker, 1967; Stirling and Chandler, 1976,
1977; Smith et al., 1984). In addition, FoxA1 is known as a key
factor (“pioneer transcription factor”) (Zaret and Carroll, 2011;
Jozwik and Carroll, 2012; Zhang et al., 2016) which regulates the
expression of estrogen receptor alpha (Bernardo and Keri, 2012;
Liu et al., 2016; Zhang et al., 2016) and is an essential factor
for mammary branching morphogenesis (Liu et al., 2016).The
cell of origin is readily identified as the LOP cell. In the early
manifestations, the LOP cell can be found distributed along
ducts. Later, the LOP cell forms large, invasive neoplasms. The
epithelial intrinsic mechanisms have been described including
activation of the JAK2 axis, deregulation of SOCS3 and mutation
of the prolactin receptor (Chan et al., 2014; Griffith et al.,
2016).
The differences between two GKO Stat1-null strains might
be reflecting the differences in immune cells: percentages of
CD4+ T cells, CD8+ T, cells and NK cells in peripheral
blood are higher in Balb/cByJ, and granulocytes, eosinophils,
monocytes and B-cells are higher in 129S1/SvlmJ (Brayton
et al., 2012). Because of STAT1 involvement in interleukin
2 signal in T lymphocytes and NK cell lines (Frank et al.,
1995), the Stat1−/− mice were originally generated to analyze
the STAT1 involvement in NK cell activity via interferon
(IFN) dependent signals and in other cytokines’ signals (Meraz
et al., 1996). The study showed that STAT1 deficiency leads
to inactivation in IFNa and IFNg signals (Durbin et al.,
1996; Meraz et al., 1996) and has a defect in responding to
microbial pathogens (Meraz et al., 1996) and viruses (Durbin
et al., 1996; Meraz et al., 1996), but the response for other
signals (growth hormone, EGF and IL-10) were not impaired
(Meraz et al., 1996). In later study, 129: Stat1−/− was shown
to have a defect in cytolysis activity in NK cells (Lee et al.,
2000).
Our pathological analyses of the three cohorts of older
129: wild type (WT), tumor free 129: Stat1−/− and tumor-
bearing 129: Stat1−/− revealed characteristic lesions of
aging: including. ovaries with luteinized stroma and fewer
Graafian follicles. However, the hormone regulating glands
(adrenal gland, thyroid gland, and pituitary gland) were
all histologically normal. Evidence active estrus cycle was
still found in 96 weeks old mice, indicating the ovarian
hormones were still active. Although some 129: Stat1−/−
showed the defects such as ovarian cysts, not all female with
ovarian cysts developed mammary tumor, and one tumor-
bearing female had histologically normal ovaries. These
observations on ovaries and estrus cycle indicate that the
tumorigenesis in 129: Stat1−/− is not due to the lack of ovarian
hormones.
To understand the effect of the microenvironmental factors
in Stat1-null tumorigenesis, syngeneic orthotopic transplants of
Stat1-null tumor and MIN tissue into younger 129 WT and
KO were performed. Tumors were palpable earlier in WT host.
However, the tumor growth rates were almost the same in both
hosts. This still resulted in 10-100 folds larger tumor inWT at the
termination time point.
The analysis primary tumors in 129:Stat1−/− showed
that stroma adjacent to the tumor had larger infiltrates
of inflammatory cells (macrophage and T-lymphocytes) with
fibrosis as compared to other GEMM (Cardiff et al., 2006).
These observations of immune cell activities suggested that
Stat1-null tumor makes an immune-attractive tumor-adjacent
microenvironment and has an “excluded infiltrate” phenotype
(Hegde et al., 2016). To investigate the possible mechanisms, we
analyzed factors secreted from Stat1-null cell lines and found
that soluble factors inhibit macrophage migration whereas the
extracellular vesicle fraction stimulates macrophage migration.
This indicates that SASP activity in Stat1-null tumors involves
with cross talk with the microenvironment.
The point of introducing our study here is to provide
an example of analyzing aging- related tumorigenesis in the
mammary gland. First, as we discussed in above, environmental
factors (housing, cycles of circadian rhythm controlled by
light/dark cycles, diet, viral- and bacterial-infections and any
other pathogens) for maintaining mouse colony can affect
mouse phenotype. It is not easy to adjust these parameters in
every institution to compare mouse models, at least checking
viral- and bacterial-infection should be done to consider
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if immune cell activity is different or not in each mouse
colony. Our colony ismonitored using a serology profile (UC
Davis mouse level2 serogenic profile: Mouse Hepatitis Virus,
Sendai, Pneumonia Virus of Mice Reo-3, MPV, Minute Virus
of Mice (parvovirus type) NS-1, M.pul and arth, Theiler’s
Murine Encephalomyelitis Virus part of GDVII strain, Reo-
3, Lymphocytic Choriomeningitis Virus, Epidemic Diarrhea of
Infant Mice Virus, Mouse Adeno DNA Virus 1 and 2, Mouse
Noro Virus). In addition, bacterial pathogens are tested on cecum
or nasopharynx and pinworms or fur mites are also routinely
checked (Mori et al., 2015). In our case, although specific
immune cell activities are not compared, 129: Stat1−/− at UC
Davis and Washington University showed identical mammary
tumorigenesis phenotypes, especially for T50 in nulliparous and
parous dependent and tumor subtypes (Chan et al., 2012; Mori
et al., 2017).
Secondly, wild type and KO were necropsied to find causative
factors of mammary tumorigenesis and cause of death (COD)
especially for evidence associated with aging. The guidelines of
for determination for of COD contributing to COD (CCOD) or
cause of morbidity are as suggested by The National Center for
Toxicological Research (NCTR), which is the important for aging
studies (Kodell et al., 1995; Brayton et al., 2012).
Third, syngeneic orthotropic transplantation was used to
understand some microenvironmental effects. Since many of
GEMM have targeted gene regulation for embryonic stages
or hormone dependency or inducible gene expression system
multiple cell types could be targeted in these GEMM. In our
case, Stat1 gene deletion could affect any Stat1 expressing cells.
Therefore, the tissue microenvironment developed abnormally,
or the tumor cells generated a unique microenvironment, or
gene modification affected the microenvironment in Stat1 GKO.
Some the non-epithelial effects can be eliminated using syngeneic
orthotopic transplantation. This approach worked very well
for the early experiments with younger host. Unfortunately,
only young hosts were available for transplantation. Testing
hypothesis in aged host mice will have to held for our
future experiments. Syngeneic orthotopic transplantation is also
useful for studying spatiotemporal factors in aging or cancer
research.
Fourth, the understanding of targeted aging or
microenvironmental factors in mammary tumorigenesis,
can be analyzed applying these techniques. These can provide a
broad-context picture of the biology of aging and cancer.
SUMMARY
GEMM have been generated for analyzing functions of a gene
in physiopathological events and are often crossed with other
GEMM to further investigate context dependent biological
phenomena. In breast cancer research, GEMM made for
analyzing the gene involvement for mammary tumorigenesis
have been used to study tumor progression in mammary
glands and metastasis. Although a longer tumor latency
(T50 value) suggests involvement of the target molecule in
aging-dependent mammary tumorigenesis, few studies have
defined how aging and impacts tumor initiation or tumor
progression. This lack research effort might be explained by
multiple issues: difficulties in separating the aging effect from
tumorigenesis; the commitment of time to complete a project;
and the cost and the effort required to model aging are all
confounding. Tumorigenesis in most GEMM is too rapid to
permit aging related comparisons. Complex parameters must
be considered to understand entire in vivo biological system.
Finally, lack of good GEMM for studying aging and mammary
tumorigenesis simultaneously has hindered progress in this
area.
129: Stat1−/− is a model for the study of age-related
mammary tumorigenesis. The frequency of tumorigenesis, T50
and tumor subtype of the model provides a model that
is an age-related ER+ tumor model. The origin and the
fate of LOP cells needs to be identified and coupled with
immunoediting and microenvironment factors. One envisions
that experiments with this model will provide a complex but
informative picture of breast cancer. This will be major challenge
for investigators including us but will lead to much sounder
understanding. Fortunately, these issues are not limited to
the 129: Stat1−/− model but also applicable to many other
GEMM.
The challenge is to understand the complex biology in each
GEMM. It very important to share experimental information,
data, and materials in addition to each publication. This will
facilitate collaborative research by reducing time, cost and mouse
usage and lead to an improved understanding of the biology of
cancer in aging.
SHARING GEMM DERIVED INFORMATION
AND MATERIALS ON AGING
Databases available for sharing information:
Genome informatics (MGI: http://www.informatics.
jax.org/), Mouse tumor biology database (http://tumor.
informatics.jax.org/mtbwi/index.do), European mutant mouse
pathology database (http://pathbase.net/), National Cancer
Informatics Program (NCIP) hub for a collaboratory for
cancer research (https://nciphub.org/). These databases give
basic information of registered mouse models. However, each
institution’s environmental information for maintaining mouse
colony and serogenic profile for each GEMM is not well-
documented. Available tissue samples with detailed conditions
have not been organized. There is an activity of “Sharing
Experimental Animal Recourses, Coordinating Holdings,” which
suggests sharing the materials from experimental animal
models to reduce animal use and accelerate collaborative
research. Especially for sharing aging research models,
sharing hub website has been developed (www.sharmuk.
org). Our website, Center for Genomic Pathology, additionally
provides online courses for educating researchers (www.
ctrgenpath.org). These are important to further understand
each GEMM characteristics by comparing with a certain
condition, which facilitate the cancer and aging related
research.
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